Altace Revascularization Benefit Is Clear But Inappropriate For Label - Cmte.
Executive Summary
King Pharmaceuticals' ACE inhibitor Altace is clearly beneficial in reducing the need for revascularization, but inclusion of the claim in labeling may inappropriately influence clinical practice, members of FDA's Cardio-Renal Drugs Advisory Committee said.